<DOC>
	<DOCNO>NCT00003569</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Chemoprotective drug dimesna may protect normal cell side effect chemotherapy . PURPOSE : This phase I trial study side effect best dose dimesna treat patient solid tumor receive cisplatin paclitaxel .</brief_summary>
	<brief_title>Dimesna Treating Patients With Solid Tumors Who Are Undergoing Treatment With Cisplatin Paclitaxel</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose ( MTD ) dimesna administer prior cisplatin paclitaxel patient solid tumor . - Determine dose related qualitative quantitative side effect dimesna administer schedule patient . - Determine minimum safe volume intravenous hydration determination MTD dimesna patient . - Investigate possible protective side effect dimesna reduce prevent development cisplatin induced nephrotoxicity observe possible protective effect cisplatin paclitaxel relate neurotoxicity myelosuppression patient . - Investigate pharmacokinetic behavior dimesna plasma urine schedule administration patient population . OUTLINE : This dose-escalation , two-stage , multicenter study . During stage I , patient receive single dose dimesna IV 15 minute 7 day prior chemotherapy . Patients receive paclitaxel IV 3 hour follow dimesna IV 15-30 minute follow immediately cisplatin IV 1 hour day 1 every 3 week . Patients continue course paclitaxel , dimesna , cisplatin every 3 week absence disease progression unacceptable toxicity 6 course . In stage I , cohorts 3-6 patient receive escalate dos dimesna maximum tolerate dose ( MTD ) reach . The MTD define high dose 1 6 patient experience dose limit toxicity ( DLT ) . The MTD dimesna use stage II study , volume pre post cisplatin intravenous saline hydration reduce cohort 3-6 patient . The MTD intensity cisplatin define least saline hydration volume 1 6 patient experience DLT . PROJECTED ACCRUAL : Approximately 35 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer , ovarian carcinoma , squamous cell carcinoma head neck , tumor type standard treatment exists , tumor type fail standard therapy Paclitaxel cisplatin combination therapy must appropriate option treat disease No potentially curable type cancer ( e.g. , newly diagnose testicular cancer ) PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 6 week Hematopoietic : WBC great 4,000/mm^3 Absolute neutrophil count great 1,500/mm^3 Platelet count great 100,000/mm^3 Hepatic : Bilirubin normal SGOT SGPT normal Renal : Creatinine normal Creatinine clearance least 60 mL/min Cardiovascular : No evidence congestive heart failure No uncontrolled moderate severe hypertension Includes patient persistent elevate systolic blood pressure great 170 mm Hg diastolic blood pressure great 100 mm Hg 1 month medical treatment Other : No active infection No perceive actual clinical risk cisplatin induced toxicity exceed clinical benefit use cisplatin therapy No known history severe hypersensitivity polyoxyl 35 castor oil vehicle No severe medical problem unrelated malignancy would interfere compliance study Not pregnant Effective contraception require fertile patient PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent colony stimulate factor except febrile neutropenia No concurrent aminoglycoside therapy except febrile neutropenia life threaten infection No concurrent immunotherapy Chemotherapy : At least 6 week since prior nitrosoureas mitomycin At least 3 week since prior chemotherapy No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy measurable disease Surgery : At least 2 week since prior major surgery Other : No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>stage III non-small cell lung cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>stage III squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>stage III squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>neurotoxicity</keyword>
	<keyword>recurrent salivary gland cancer</keyword>
	<keyword>stage IV salivary gland cancer</keyword>
	<keyword>salivary gland squamous cell carcinoma</keyword>
	<keyword>stage III salivary gland cancer</keyword>
</DOC>